Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

The pneumococcal conjugate vaccine – codenamed PCV21/GBP410 ... slightly down on the same period of 2023. MSD (known as Merck & Co in the US and Canada), meanwhile, recorded $647 million ...

Ursinus College has received a $4 million pledge that when realized will be among the largest gifts ever to the 156-year-old ...

Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the moment with its Prevnar franchise, Merck has multiple ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more ... Prevnar franchise has new competition with Merck’s Capvaxive. Merck’s offering counters Prevnar 20's ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

We recently compiled a list of the 10 Best Russell 2000 Stocks to Invest in According to Analysts. In this article, we are ...